Literature DB >> 12116375

G(1)/S but not G(0)/G(1)cell fraction is related to 5-fluorouracil cytotoxicity.

J-F Mirjolet1, C Didelot, M Barberi-Heyob, J-L Merlin.   

Abstract

BACKGROUND: Bromodeoxyuridine (BrdU) cell cycle analysis using flow cytometry is of clinical interest for making treatment decisions or for predicting response and survival, through proliferation rate (labeling index or S-phase fraction) assessment or T(pot) calculation. Thymidylate synthase expression was tested in vitro, in vivo, and clinically as a prognostic factor for 5-fluorouracil (5FU) sensitivity. However, results were still controversial. Moreover, we had reported that 5FU sensitivity was related to the labeling index of untreated cell cultures.
METHODS: We used six human cancer cell lines that exhibited a wide range of 5FU sensitivity. Cell cycle analysis was performed using flow cytometry monovariate propidium iodide (PI) analysis and bivariate distributions of BrdU incorporation versus DNA content. 5FU sensitivity was assayed using a 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl-2H-tetrazolium bromide (MTT) colorimetric assay.
RESULTS: In all cell lines, 5FU exposure resulted in a statistically significant G(1)/S accumulation. No statistically significant relationship was seen between G(0)/G(1) delay determined by monovariate analysis and 5FU sensitivity. However, 5FU sensitivity was statistically correlated to the labeling index and G(1)/S subpopulation assessed with bivariate analysis using BrdU incorporation versus DNA content.
CONCLUSIONS: Cellular proliferation parameters using BrdU incorporation are more informative than PI for in vitro 5FU sensitivity. Because BrdU incorporation could be assessed clinically, it could also be informative for 5FU clinical response prediction. Copyright 2002 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12116375     DOI: 10.1002/cyto.10087

Source DB:  PubMed          Journal:  Cytometry        ISSN: 0196-4763


  9 in total

1.  Ultrasound-activated agents comprised of 5FU-bearing nanoparticles bonded to microbubbles inhibit solid tumor growth and improve survival.

Authors:  Caitlin W Burke; Eben Alexander; Kelsie Timbie; Alexander L Kilbanov; Richard J Price
Journal:  Mol Ther       Date:  2013-10-31       Impact factor: 11.454

2.  Human mutations in methylenetetrahydrofolate dehydrogenase 1 impair nuclear de novo thymidylate biosynthesis.

Authors:  Martha S Field; Elena Kamynina; David Watkins; David S Rosenblatt; Patrick J Stover
Journal:  Proc Natl Acad Sci U S A       Date:  2014-12-29       Impact factor: 11.205

3.  Predictive value of Ki67 and p53 in locally advanced rectal cancer: correlation with thymidylate synthase and histopathological tumor regression after neoadjuvant 5-FU-based chemoradiotherapy.

Authors:  Christiane Jakob; Torsten Liersch; Wolfdietrich Meyer; Heinz Becker; Gustavo-B Baretton; Daniela-E Aust
Journal:  World J Gastroenterol       Date:  2008-02-21       Impact factor: 5.742

4.  DAFODIL: A novel liposome-encapsulated synergistic combination of doxorubicin and 5FU for low dose chemotherapy.

Authors:  Kathryn M Camacho; Stefano Menegatti; Douglas R Vogus; Anusha Pusuluri; Zoë Fuchs; Maria Jarvis; Michael Zakrewsky; Michael A Evans; Renwei Chen; Samir Mitragotri
Journal:  J Control Release       Date:  2016-03-24       Impact factor: 9.776

5.  Up-regulation of cyclooxygenase-2-derived prostaglandin E(2) in colon cancer cells resistant to 5-fluorouracil.

Authors:  Cheol Hee Choi; Tae Bum Lee; Yeon Ah Lee; Suk Choi; Kyung Jong Kim
Journal:  J Korean Surg Soc       Date:  2011-08-03

6.  Inhibition of post-transcriptional steps in ribosome biogenesis confers cytoprotection against chemotherapeutic agents in a p53-dependent manner.

Authors:  Russell T Sapio; Anastasiya N Nezdyur; Matthew Krevetski; Leonid Anikin; Vincent J Manna; Natalie Minkovsky; Dimitri G Pestov
Journal:  Sci Rep       Date:  2017-08-22       Impact factor: 4.379

7.  Damaged DNA binding protein 2 plays a role in breast cancer cell growth.

Authors:  Zilal Kattan; Sophie Marchal; Emilie Brunner; Carole Ramacci; Agnès Leroux; Jean Louis Merlin; Lionel Domenjoud; Michel Dauça; Philippe Becuwe
Journal:  PLoS One       Date:  2008-04-23       Impact factor: 3.240

8.  A novel approach in the treatment of neuroendocrine gastrointestinal tumors: additive antiproliferative effects of interferon-gamma and meta-iodobenzylguanidine.

Authors:  Michael Höpfner; Andreas P Sutter; Alexander Huether; Gudrun Ahnert-Hilger; Hans Scherübl
Journal:  BMC Cancer       Date:  2004-05-21       Impact factor: 4.430

9.  [18F]FDG and [18F]FLT uptake in human breast cancer cells in relation to the effects of chemotherapy: an in vitro study.

Authors:  W G E Direcks; S C Berndsen; N Proost; G J Peters; J Balzarini; M D Spreeuwenberg; A A Lammertsma; C F M Molthoff
Journal:  Br J Cancer       Date:  2008-08-05       Impact factor: 7.640

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.